TXMD vs. LSTA, MEIP, SYBX, INDP, ONTX, LUMO, BFRG, BIOR, VINC, and CPIX
Should you be buying TherapeuticsMD stock or one of its competitors? The main competitors of TherapeuticsMD include Lisata Therapeutics (LSTA), MEI Pharma (MEIP), Synlogic (SYBX), Indaptus Therapeutics (INDP), Onconova Therapeutics (ONTX), Lumos Pharma (LUMO), Bullfrog AI (BFRG), Biora Therapeutics (BIOR), Vincerx Pharma (VINC), and Cumberland Pharmaceuticals (CPIX). These companies are all part of the "pharmaceutical preparations" industry.
TherapeuticsMD (NASDAQ:TXMD) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation, community ranking and media sentiment.
30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are owned by institutional investors. 1.2% of TherapeuticsMD shares are owned by insiders. Comparatively, 21.6% of Lisata Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
TherapeuticsMD has higher revenue and earnings than Lisata Therapeutics.
In the previous week, Lisata Therapeutics had 2 more articles in the media than TherapeuticsMD. MarketBeat recorded 4 mentions for Lisata Therapeutics and 2 mentions for TherapeuticsMD. Lisata Therapeutics' average media sentiment score of 0.37 beat TherapeuticsMD's score of 0.00 indicating that Lisata Therapeutics is being referred to more favorably in the news media.
TherapeuticsMD received 380 more outperform votes than Lisata Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Lisata Therapeutics an outperform vote while only 62.66% of users gave TherapeuticsMD an outperform vote.
TherapeuticsMD has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500.
Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 449.45%. Given Lisata Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lisata Therapeutics is more favorable than TherapeuticsMD.
TherapeuticsMD's return on equity of -25.54% beat Lisata Therapeutics' return on equity.
Summary
Lisata Therapeutics beats TherapeuticsMD on 8 of the 14 factors compared between the two stocks.
Get TherapeuticsMD News Delivered to You Automatically
Sign up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TXMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TherapeuticsMD Competitors List
Related Companies and Tools
